National AIDS Research Institute (NARI), Pune, India, is a nodal HIV/AIDS research institute of the Indian Council of Medical Research (ICMR). The first international grant awarded to NARI in September 1992 was "Preparation for AIDS Vaccine Evaluation" (PAVE). This was followed by an NIH sponsored grant, viz., HIV Network for Prevention Trials (HIVNET) from November 1994. The HIVNET project was the largest, comprehensive epidemiological study of risk factors for HIV transmission in India and provided the first estimates of HIV incidence as well as the first documentation of clinical features of acute sero-conversion. The same site infrastructure was used for studies in acute sero-converters from 1997-1999 under a RO1 funded grant, which aimed at a more comprehensive follow-up of sero-converters and p24 antigenic individuals to study the immunopathogenesis of acute HIV infection. With initial focus on descriptive epidemiology and basic research, NARI is currently involved in clinical trials and applied research. The first clinical trial was carried out in 1998 and since then NARI has been participating in clinical trials funded by severa international and national organizations. NARI became a part of HPTN (034, 047, 052, 059 studies), ACTG (5175, 5185, 5190, 5199 studies) and vaccine trial networks (HVTN and IAVI). NARI CTU initiated the IAVI sponsored first phase I AIDS vaccine trial in India in January 2005. In response to NIH RFA (RFA-AI- 05-002) for Units for HIV/AIDS Clinical Trial Networks, NARI propose to apply to be identified as a 'Unit for HIV / AIDS Clinical Trials Network with participation in four networks, viz., Prevention of HIV infection [PTN];Optimization of clinical management including co-morbidities [ACTG];Microbicides [MTN] and Vaccine research and development [VTN]. NARI is proposing four Clinical Research Sites (CRS) at Pune city and one mere at the ICMR's National Institute for Research in Reproductive Health (NIRRH), Mumbai, a premier research organization working in basic clinical and operational research aspects of reproduction and sexual health. Both Pune and Murnbai are large industrial cities with populations of 3 million and 10 million respectively in the western high HIV prevalence state of Maharashtra in India. In view of the large susceptible and eligible populations available that would participate in clinical trials and infrastructure and expertise available at the two premier research institutes, namely, National AIDS Research Institute and Nations I Institute for Research in Reproductive Health of the ICMR in Pune and Mumbai, respectively and coupled with experience of actually conducting clinical trials, NARI is ideally placed to participate in the NIH sponsored global network of HIV/AIDS clinical trials. We feel confident that our participation in the NIH HIVAIDS clinical trial networks will compliment our national research priorities. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
3UM1AI069417-07S2
Application #
8822569
Study Section
Special Emphasis Panel (ZAI1-KS-A (M3))
Program Officer
Potter, Dara G
Project Start
2007-08-15
Project End
2015-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
7
Fiscal Year
2014
Total Cost
$167,377
Indirect Cost
$12,398
Name
National AIDS Research Institute
Department
Type
DUNS #
915223064
City
Pune
State
Country
India
Zip Code
41102-6
La Rosa, Alberto M; Harrison, Linda J; Taiwo, Babafemi et al. (2016) Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 3:e247-58
Firnhaber, Cynthia; Smeaton, Laura M; Grinsztejn, Beatriz et al. (2015) Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials 16:89-99
Touzard Romo, F; Smeaton, L M; Campbell, T B et al. (2014) Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials 15:246-60
McMahon, Deborah K; Zheng, Lu; Hitti, Jane et al. (2013) Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. Clin Infect Dis 56:1044-51
Tolley, Elizabeth E; Tsui, Sharon; Mehendale, Sanjay et al. (2012) Predicting product adherence in a topical microbicide safety trial in Pune, India. AIDS Behav 16:1808-15
Campbell, Thomas B; Smeaton, Laura M; Kumarasamy, N et al. (2012) Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 9:e1001290
Grinsztejn, Beatriz; Smeaton, Laura; Barnett, Ronald et al. (2011) Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther 16:1057-62
Kohli, Rewa; Tsui, Sharon; Mehendale, Sanjay et al. (2011) Indian married men's interest in microbicide use. AIDS Care 23:1344-9
Sahay, Seema; Mehendale, Sanjay (2011) Engaging community to support HIV prevention research. East J Med 16:168-177
Robertson, Kevin; Kumwenda, Johnstone; Supparatpinyo, Khuanchai et al. (2011) A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol 17:438-47

Showing the most recent 10 out of 11 publications